KR102607222B1 - 신규 사용 방법 - Google Patents

신규 사용 방법 Download PDF

Info

Publication number
KR102607222B1
KR102607222B1 KR1020177018865A KR20177018865A KR102607222B1 KR 102607222 B1 KR102607222 B1 KR 102607222B1 KR 1020177018865 A KR1020177018865 A KR 1020177018865A KR 20177018865 A KR20177018865 A KR 20177018865A KR 102607222 B1 KR102607222 B1 KR 102607222B1
Authority
KR
South Korea
Prior art keywords
acne
dihydroxy
isopropyl
trans
stilbene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177018865A
Other languages
English (en)
Korean (ko)
Other versions
KR20170095928A (ko
Inventor
자비에르 코테-시에라
수잔 에이치. 스미스
스티븐 엠. 프레이
Original Assignee
더마반트 사이언시즈 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더마반트 사이언시즈 게엠베하 filed Critical 더마반트 사이언시즈 게엠베하
Publication of KR20170095928A publication Critical patent/KR20170095928A/ko
Application granted granted Critical
Publication of KR102607222B1 publication Critical patent/KR102607222B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y10S514/859—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177018865A 2014-12-12 2015-12-09 신규 사용 방법 Active KR102607222B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462090908P 2014-12-12 2014-12-12
US62/090,908 2014-12-12
PCT/IB2015/059490 WO2016092493A1 (en) 2014-12-12 2015-12-09 Novel method of use

Publications (2)

Publication Number Publication Date
KR20170095928A KR20170095928A (ko) 2017-08-23
KR102607222B1 true KR102607222B1 (ko) 2023-11-29

Family

ID=55025296

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177018865A Active KR102607222B1 (ko) 2014-12-12 2015-12-09 신규 사용 방법

Country Status (11)

Country Link
US (1) US10376475B2 (enExample)
EP (1) EP3229840B1 (enExample)
JP (3) JP7313117B2 (enExample)
KR (1) KR102607222B1 (enExample)
AR (1) AR102973A1 (enExample)
AU (1) AU2015358910B2 (enExample)
CA (1) CA2970739C (enExample)
DK (1) DK3229840T5 (enExample)
ES (1) ES2829637T3 (enExample)
TW (1) TWI692357B (enExample)
WO (1) WO2016092493A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107666902B (zh) 2015-05-21 2021-09-21 德玛万科学有限责任公司 局部药物组合物
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
US20170231922A1 (en) * 2016-02-16 2017-08-17 Horizon GenoMed Therapeutics, Inc 3, 5-dihydroxy-4-isopropylstilbene (dhis) as miticidal agent and its therapeutic uses
US10647649B2 (en) 2017-11-10 2020-05-12 Dermavant Sciences GmbH Process for preparing tapinarof
US10967197B2 (en) 2018-08-29 2021-04-06 Azulite, Inc. Phototherapy devices and methods for treating truncal acne and scars
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
WO2020174467A1 (en) * 2019-02-25 2020-09-03 Sol-Gel Technologies Ltd. Treatment of psoriasis with topical tapinarof- tazarotene combination compositions
US20220202737A1 (en) * 2019-03-26 2022-06-30 Sol-Gel Technologies Ltd. Treatment of hidradenitis suppurativa with tapinarof compositions
WO2021014453A1 (en) * 2019-07-24 2021-01-28 Sol-Gel Technologies Ltd. Topical jak inhibitor combination compositions for treatment of inflammatory skin conditions
WO2021059281A1 (en) * 2019-09-26 2021-04-01 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical combination compositions comprising tapinarof and an additional ahr activator
EP4061332A4 (en) * 2019-11-24 2023-11-29 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical compositions comprising tapinarof and a pde4 inhibitor
CN116265421B (zh) * 2021-12-17 2024-01-02 上海泽德曼医药科技有限公司 用于预防或治疗中枢神经系统相关疾病的化合物
WO2023109859A1 (zh) * 2021-12-15 2023-06-22 上海泽德曼医药科技有限公司 二苯乙烯类化合物及其在用于预防和/或治疗中枢神经系统相关疾病中的应用
WO2024050431A2 (en) * 2022-08-30 2024-03-07 Dermavant Sciences GmbH Tapinarof and analogs thereof for use in treating ahr mediated diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003695A1 (en) 1993-07-27 1995-02-09 Agro-Biotech Corporation Novel fungicidal properties of metabolites, culture broth, stilbene derivatives and indole derivatives produced by the bacteria xenorhabdus and photorhabdus spp.
US5747482A (en) * 1996-07-30 1998-05-05 Bernstein; Lawrence R. Methods and compositions to inhibit keratinocyte proliferation
US7321050B2 (en) 1999-12-06 2008-01-22 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
CN1319959C (zh) 1999-12-06 2007-06-06 天济药业（深圳）有限公司 抗发炎、治疗牛皮癣和抑制蛋白质致活酶的羟基芪、芪衍生物及其类似物
JP2006508930A (ja) * 2002-10-01 2006-03-16 ウェリケム バイオテック インコーポレーテッド 新規生物活性ジフェニルエテン化合物およびその治療への適用
FR2917427B1 (fr) * 2007-06-18 2009-08-21 Galderma Res & Dev Inhibiteurs de tace dans le traitement de l'acne
WO2009108762A2 (en) * 2008-02-26 2009-09-03 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
US20100003315A1 (en) * 2008-07-02 2010-01-07 Willeford Kenneth L Method and Composition for the Treatment of Skin Conditions
CN101531571B (zh) 2009-04-17 2013-03-20 河北科技大学 六次甲基四胺氧化合成二苯乙烯类化合物的方法
CN101633606B (zh) 2009-08-13 2014-08-27 河北科技大学 盐酸非均相氯代合成茋类化合物的方法
CN101648851B (zh) 2009-09-03 2012-10-10 河北科技大学 (e)-3,5-二羟基-4-异丙基二苯乙烯的清洁制备方法
CN101830764A (zh) 2010-05-05 2010-09-15 河北科技大学 利用Pfitzner-moffatt氧化反应合成茋类化合物的方法
CN101838173A (zh) 2010-05-07 2010-09-22 河北科技大学 利用Kornblum氧化反应合成茋类化合物的方法
JP6279467B2 (ja) * 2011-06-27 2018-02-14 ガルデルマ・リサーチ・アンド・デヴェロップメント ざ瘡についての新規ｔｈ１７分化マーカーおよびその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Advances in psoriasis, a multisystemic guide (2014.8.28.) 1부.*
PLoS One 9(8) e105234 (2014.8.) 1부.*

Also Published As

Publication number Publication date
DK3229840T5 (da) 2020-11-16
CA2970739A1 (en) 2016-06-16
EP3229840B1 (en) 2020-09-09
KR20170095928A (ko) 2017-08-23
WO2016092493A1 (en) 2016-06-16
AU2015358910B2 (en) 2019-01-24
JP2021152018A (ja) 2021-09-30
US10376475B2 (en) 2019-08-13
AU2015358910A1 (en) 2017-06-29
EP3229840A1 (en) 2017-10-18
ES2829637T3 (es) 2021-06-01
JP2023123554A (ja) 2023-09-05
AR102973A1 (es) 2017-04-05
US20170360719A1 (en) 2017-12-21
TWI692357B (zh) 2020-05-01
CA2970739C (en) 2023-10-03
DK3229840T3 (da) 2020-11-09
JP2017537936A (ja) 2017-12-21
JP7313117B2 (ja) 2023-07-24
TW201639548A (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
KR102607222B1 (ko) 신규 사용 방법
Han et al. The antimicrobial effect of CEN1HC-Br against Propionibacterium acnes and its therapeutic and anti-inflammatory effects on acne vulgaris
JP6944399B2 (ja) プロバイオティクス細菌
Jiang et al. The effect of adipose tissue derived MSCs delivered by a chemically defined carrier on full-thickness cutaneous wound healing
US20150017227A1 (en) Methods and Compositions for Treating Skin Diseases and Conditions
Téllez-Pérez et al. Cholecalciferol (vitamin D) differentially regulates antimicrobial peptide expression in bovine mammary epithelial cells: implications during Staphylococcus aureus internalization
GB2542797A (en) Use of cannabinoids in the treatment of inflammatory skin diseases
CN102256608A (zh) 含有血单核细胞培养物的上清液的药物制剂
WO2007011606A2 (en) USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
RU2687151C2 (ru) Тетрапептиды, полученные из с-х-с-хемокинов человека, подходящие для лечения различных состояний кожи
JP2019513769A (ja) アトピー性皮膚炎を処置するためのグラム陰性種の使用
JP2015500820A (ja) Ｅｇｆｒ阻害の有害反応を予防または処置するための組成物
AU2018260096B2 (en) Rucaparib, Talazoparib, Veliparib, Olaparib and AZD 2461 for treating impaired skin wound healing
US20230193276A1 (en) Composition of drug targets and method of using thereof
Zhou et al. Microneedle delivery platform integrated with Staphylococcus epidermidis-derived extracellular vesicles-based nanoantibiotics for efficient bacterial infection atopic dermatitis treatment
KR20020044851A (ko) 여드름 예방 및 치료용 스핑고리피드 조성물
WO2012105706A1 (ja) ケロイド治療剤
Song et al. Liushen Wan alleviates the virulence and inflammation of Staphylococcus aureus via NLRP3 inflammasome and TLR2-NF-κB/p38 MAPK signaling pathways
US11311484B2 (en) Methods and compositions for treating skin afflictions
TW201711696A (zh) 用於促進傷口癒合的吳郭魚抗菌胜肽
US20150051147A1 (en) Methods for treating hidradenitis suppurativa
RU2822544C2 (ru) Терапевтическое применение окислительных гипотонических кислотных растворов
Naresh EVALUATION OF WOUND HEALING POTENTIAL OF CURCUMIN AND DEFEROXAMINE COMBINATION IN CUTANEOUS WOUND HEALING IN RATS THESIS
오윤실 Inhibitory Effects of Orobol on Heat-killed Propionibacterium acnes-induced Inflammation and Hyperproliferation of HaCaT Keratinocytes
Granstein et al. 016 Calcitonin gene-related peptide (CGRP)-treated primary dermal microvascular endothelial cells (pDMECs) bias the outcome of antigen (Ag) presentation toward the Th17 pole

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000